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ABSTRACT
This study examined the hepatobiliary disposition of troglita-
zone (TGZ) and metabolites [TGZ sulfate (TS), TGZ glucuronide
(TG), and TGZ quinone (TQ)] over time in rat and human sand-
wich-cultured hepatocytes (SCH). Cells were incubated with
TGZ; samples were analyzed for TGZ and metabolites by liquid
chromatography-tandem mass spectrometry. SCH mimicked
the disposition of TGZ/metabolites in vivo in rats and humans;
TGZ was metabolized primarily to TS and to a lesser extent to
TG and TQ. In human SCH, the biliary excretion index (BEI) was
negligible for TGZ and TQ, 16% for TS, and 43% for TG
over the incubation period; in rat SCH, the BEI for TS and TG
was 13 and 41%, respectively. Hepatocyte accumulation of
TS was extensive, with intracellular concentrations ranging
from 132 to 222 M in rat SCH; intracellular TGZ concentra-
tions ranged from 7.22 to 47.7 M. In human SCH, intracellular
TS and TGZ concentrations ranged from 136 to 160 M and
from 49.4 to 84.7 M, respectively. Pharmacokinetic modeling
and Monte Carlo simulations were used to evaluate the impact
of modulating the biliary excretion rate constant (Kbile) for TS on
TS accumulation in hepatocytes and medium. Simulations
demonstrated that intracellular concentrations of TS may in-
crease up to 3.1- and 5.7-fold when biliary excretion of TS was
decreased 2- and 10-fold, respectively. It is important to note
that altered hepatobiliary transport and the extent of hepato-
cyte exposure may not always be evident based on medium
concentrations (analogous to systemic exposure in vivo). Phar-
macokinetic modeling/simulation with data from SCH is a use-
ful approach to examine the impact of altered hepatobiliary
transport on hepatocyte accumulation of drug/metabolites.
Troglitazone (TGZ; Rezulin), a peroxisome proliferator-
activated receptor  agonist, was withdrawn from the mar-
ket in 2000 due to several cases of severe idiosyncratic
liver injury (Graham et al., 2003; Smith, 2003). Several
mechanisms for the hepatotoxicity of TGZ have been pro-
posed (Smith, 2003; Masubuchi, 2006), including inhibi-
tion of the bile salt export pump (Bsep, ABCB11), the
hepatic transport protein primarily responsible for biliary
excretion of bile acids, by TGZ and TGZ sulfate (TS) (Funk
et al., 2001). Bsep inhibition may cause hepatic accumula-
tion of detergent-like bile acids, thereby resulting in hep-
atocellular injury. It is interesting to note that TS is a
more potent inhibitor of Bsep (IC50  0.4 – 0.6 M) than
TGZ (IC50  3.9 M) (Funk et al., 2001), emphasizing the
importance of metabolite-mediated hepatotoxicity in addi-
tion to that of the parent drug.
TGZ is metabolized extensively by the liver in humans as
well as in rats. The in vivo metabolic profile and disposition
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of TGZ in rats are similar to that in humans. In humans, TGZ
is metabolized primarily to a sulfate conjugate mostly via
sulfotransferase 1A3 (Honma et al., 2002) and also to a
glucuronide conjugate mostly via UDP-glucuronosyltrans-
ferase 1A1 (Yoshigae et al., 2000; Watanabe et al., 2002);
TGZ also is oxidized to a quinone derivative by cytochrome
P450 isozymes CYP3A4 and CYP2C8 (Yamazaki et al., 1999).
After oral administration of TGZ for 7 days to humans, the
area under the plasma concentration versus time curve at
steady state (AUCss) for TS was 7- to 10-fold higher than
that of TGZ; the plasma AUCss for TGZ quinone (TQ) was
comparable with that of TGZ, but the AUCss for TG was only
20 to 40% of that for TGZ (Loi et al., 1999). Similarly, after
oral administration of [14C]TGZ to male rats, the AUC of TS
accounted for 89% of the AUC of total plasma radioactivity,
whereas the AUC of TGZ and TG was only 5 and 1% of the
AUC of total plasma radioactivity, respectively (Kawai et al.,
1997). After intravenous administration of [14C]TGZ to male
rats, the biliary excretion of TS and TG was 61 and 2% of the
dose, respectively, whereas TGZ and TQ recovery in bile
accounted for less than 0.1% of the dose (Kawai et al., 1997).
Because TGZ is metabolized extensively and little parent
compound is excreted unchanged into urine or bile (Kawai et
al., 1997), the total body clearance of TGZ is governed by its
metabolic clearance (Izumi et al., 1996).
Sensitive and rapid in vitro screening tools to predict hep-
atotoxicity are needed in the pharmaceutical industry. Pri-
mary hepatocytes remain an important tool for studying the
metabolism and hepatotoxic potential of xenobiotics. Hepa-
tocytes cultured in a single layer of collagen are suitable for
cytotoxicity assays, but the use of this tool is limited due to
loss of metabolic activity and short survival periods (Hewitt
et al., 2007). Hepatocytes cultured in a sandwich configura-
tion between layers of extracellular matrix have overcome
many of the limitations of conventional hepatocyte culture
because the cells repolarize, regain their proper morphology,
and maintain liver-specific metabolic activity, including sta-
ble expression of cytochrome P450 enzymes over longer times
(Liu et al., 1998, 1999a,b,c; Hamilton et al., 2001; Hewitt et
al., 2007; Mingoia et al., 2007). Furthermore, sandwich-cul-
tured hepatocytes (SCH) develop functional networks of bile
canalicular structures between cells that are sealed by tight
junctions (LeCluyse et al., 1994; Liu et al., 1999b). Measure-
ments of biliary excretion of drugs and metabolites in hu-
mans are often indirect or require invasive procedures, but
cells and canalicular networks of SCH are directly accessible,
allowing the quantification of substrates and metabolites
excreted into the medium, retained within the cell, or ex-
creted into the bile (Liu et al., 1999a,c; Hoffmaster et al.,
2004; Turncliff et al., 2006).
The present study used rat and human SCH to examine
the metabolism of TGZ, governed primarily by phase II con-
jugation, and the hepatobiliary disposition of TGZ and its
derived metabolites. Moreover, the ability of this in vitro
system to approximate the in vivo disposition of TGZ and
metabolites reported previously in rats and humans was
assessed. A pharmacokinetic model was developed and used
to estimate key parameters governing the hepatobiliary dis-
position of TGZ and metabolites in rat SCH. Because vari-
ability in results from Monte Carlo simulations may repre-
sent an approximation of variability between cells in culture,
Monte Carlo simulations were conducted to explore the in-
fluence of changes in parameter estimates, analogous to he-
patic transport modulation, on the simulated hepatobiliary
disposition of TGZ and metabolites.
Materials and Methods
Chemicals. Penicillin-streptomycin solution, dexamethasone
(DEX), Hanks’ balanced salts solution (HBSS), HBSS modified
(HBSS without Ca2 and Mg, with 0.38 g/l EGTA), collagenase
(type IV), and Triton X-100 were purchased from Sigma-Aldrich (St.
Louis, MO). Dulbecco’s modified Eagle’s medium (DMEM) and MEM
nonessential amino acids were purchased from Invitrogen (Carlsbad,
CA). Insulin/transferrin/selenium culture supplement, BioCoat cul-
ture plates, and Matrigel extracellular matrix were purchased from
BD Biosciences Discovery Labware (Bedford, MA). TGZ was pur-
chased from Toronto Research Chemicals Inc. (North York, ON,
Canada). TS, TG, and TQ were kindly provided by Daiichi-Sankyo
Co., Ltd. (Tokyo, Japan). All other chemicals and reagents were of
analytical grade and were readily available from commercial
sources.
Hepatocyte Culture. Male Wistar rats (220–300 g; Charles
River Laboratories, Inc., Raleigh, NC) were maintained on a 12-h
light/dark cycle with free access to water and rodent chow. The
Institutional Animal Care and Use Committee of The University of
North Carolina at Chapel Hill approved all procedures. Rat hepato-
cytes were isolated using a two-step collagenase perfusion method as
described previously (Liu et al., 1999b). Hepatocytes were plated at
a density of 1.75  106 cells/well on six-well BioCoat plates in DMEM
(1.5 ml) containing 5% fetal bovine serum, 10 M insulin, 1 M DEX,
2 mM L-glutamine, 1% MEM nonessential amino acids, 100 units
penicillin G sodium, and 100 g of streptomycin sulfate. Hepatocytes
were allowed to attach 2 h, and the medium was changed to remove
unattached cells. Cells were overlaid 24 h later with BD Matrigel
at a concentration of 0.25 mg/ml in 2 ml/well ice-cold DMEM sup-
plemented with 0.1 mM MEM nonessential amino acids, 2 mM
L-glutamine, 100 units of penicillin G sodium, 100 g of streptomy-
cin, 1% insulin/transferrin/selenium, and 0.1 M DEX. CellzDirect
(Durham, NC) kindly provided human hepatocytes cultured in six-
well plates, seeded at a density of 1.5  106 cells/well and overlaid
with Matrigel. Table 1 shows demographics of human liver donors.
Human cells were cultured in the same medium as rat hepatocytes.
Both rat and human hepatocytes were cultured at 37°C in a humid-
ified incubator with 95% O2 and 5% CO2. Medium was changed daily
until the experiments were conducted.
Metabolism of TGZ and Accumulation of Parent and Me-
tabolites in Medium, Cells, and Bile in Rat and Human SCH.
Modulation of Ca2 in the incubation buffer was used to manipulate
the tight junctions sealing the canalicular networks between cells. In
Ca2-containing standard buffer (HBSS), tight junction integrity is
preserved and substrates are excreted into the bile canaliculi; incu-
bation of cells in Ca2-free buffer (HBSS modified) disrupts the tight
junctions, opens the canalicular spaces, and canalicular contents are
released into the incubation medium (Liu et al., 1999c). Subtraction
of the amount of substrate accumulated in cells after a preincubation
in Ca2-free buffer from the accumulated amount in cells  bile after
preincubation with Ca2-containing buffer yields the amount of sub-
strate excreted into the canalicular networks.
To evaluate metabolism of TGZ, day-4 cells (rat; n  3 livers) and
TABLE 1
Demographics of human liver donors
Donor Age Gender Ethnicity Co-Medications
yr
1 36 Female Caucasian Oral contraceptive,
hydrochlorothiazide
2 64 Female Caucasian Atorvastatin, amlodipine,
benazepril, alendronate
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day 8 or day 10 cells (human; n  2 livers) were incubated at 37°C for
10, 20, 30, 60, 90, and 120 min for rat SCH and for 30, 60, and 120
min for human SCH, with an initial concentration of 10 M TGZ in
the culture medium. Aliquots of medium were removed at each time
point, and samples were diluted with methanol [1:2 (v/v)]. At the
designated time, cells were washed twice and incubated at 37°C for
5 min with HBSS with Ca2 (cells  bile) or without Ca2 (cells).
After incubation, buffer was aspirated and cells were lysed with 1 ml
of 70%:30% (v/v) methanol/water, and sonicated for 20 s. Medium,
cells and cells  bile lysate samples were stored at less than 70°C
until analysis.
Transport of TGZ, and Preformed TS and TG Metabolites in
Rat SCH. To confirm transport of TGZ and its preformed metabo-
lites in rat SCH, medium was aspirated from cells on day 4, and cells
were rinsed twice and then preincubated for 10 min at 37°C with 2
ml of warmed standard buffer (cells  bile) or Ca2-free HBSS buffer
(cells). Medium was aspirated and cells were treated with 5 M TGZ,
TS, or TG in 1.5 ml of standard buffer for 10 min. After incubation,
the dosing medium was removed, and cells were washed three times
with 2 ml of ice-cold standard buffer. The wash buffer was aspirated,
cells were lysed by adding 1 ml of 70%:30% (v/v) methanol/water, and
samples were sonicated for 20 s with a sonic dismembrator (model
100; Thermo Fisher Scientific, Waltham, MA). Cells and cells  bile
lysate samples were stored at less than 70°C until analysis. Treat-
ments were performed in triplicate in n  1 experiment (TGZ) or n 
3 experiments (TS and TG).
Sample Analysis. Substrate accumulation was corrected for non-
specific binding to the extracellular matrix by subtracting accumu-
lation in Matrigel-coated BioCoat plates without cells. The BCA
protein assay (Pierce Chemical., Rockford, IL) was used to quantify
total protein concentration in cell lysate samples using bovine serum
albumin as the reference standard, and accumulation was normal-
ized to protein concentration. To account for the incompatibility of
the protein assay with methanol, the average protein concentration
for standard HBSS or Ca2-free HBSS incubations in a representa-
tive plate from the same liver preparation was used to normalize
accumulation.
The medium and cells or cells  bile lysate samples were centri-
fuged at 12,000g for 2 min at 4°C, and the supernatant was diluted
1:6 (v/v) with 79%:21% (v/v) methanol/water containing an internal
standard (ethyl warfarin). A solvent delivery system (Shimadzu, Co-
lumbia, MD) and a Leap HTC Pal thermostated autosampler (LEAP
Technologies, Carrboro, NC) connected to an Applied Biosystems API
4000 triple quadruple mass spectrometer with a TurboSpray ion source
(Applied Biosystems, Foster City, CA) were used for analysis. Tuning,
operation, integration, and data analysis were performed in negative
ionization mode using multiple reaction monitoring (Analyst software
version 1.4.1; Applied Biosystems). Separation was accomplished us-
ing an Aquasil C18, 50-  2.1-mm column, with a 5-m particle size
(Thermo Fisher Scientific). Analysis required 15 l of sample and a
solvent flow of 0.75 ml/min. Initial gradient conditions (80% 10 mM
ammonium acetate aqueous solution and 20% methanol) were held
for 0.8 min. From 0.8 to 1.5 min, the mobile phase composition
increased linearly to 60% methanol, and the eluent was directed to
the mass spectrometer. From 1.5 to 4 min, the mobile phase compo-
sition increased linearly to 65% methanol. At 4.1 min, the methanol
composition was increased to 90%. The flow was held at 90% meth-
anol until 4.3 min. At 4.4 min, the column was equilibrated with 80%
10 mM ammonium acetate aqueous solution. The total run time,
including equilibration, was 5 min per injection. Eight point cal-
ibration curves (5–5000 nM) were constructed as composites of
TGZ (440.03397.1), TS (520.23440.1), TG (616.23440.1), and
TQ (456.13413.1) by using peak area ratios of analyte and ethyl
warfarin (320.83160.9). All points on the curves back-calculated
to within  15% of the nominal value. Care was taken to minimize
the light-sensitive degradation of TGZ during all experimental
procedures.
B-CLEAR technology (Qualyst, Inc., Research Triangle Park, NC)
was used to calculate the biliary excretion index (BEI), which repre-
sents the percentage of accumulated substrate that is excreted into






Pharmacokinetic Modeling. The average rat SCH accumula-
tion data for TGZ, TS, TG, and TQ were used in pharmacokinetic
modeling analysis. Several structurally distinct models were evalu-
ated, and standard model selection criteria, including Akaike’s in-
formation criterion, residual distribution, and the distribution of the
residual error, were used to identify the optimal structure. The
model scheme shown in Fig. 1 best described the disposition of TGZ
and derived metabolites in rat SCH over 120 min in the medium (M),
hepatocytes (C), and bile (B). Differential equations derived from the
model scheme in Fig. 1 (see legend for definition of parameters) were
as follows:
dXTGZ,M
dt  (Kuptake,TGZ  Kf,TQ)  XTGZ,M; XTGZ,M
0  X0 (2)
dXTS,M
dt  Kefflux,TS  XTS,C  Kuptake,TS  XTS,M; XTS,M
0  0; t  Tflux
(3)
dXTS,M
dt  Kefflux,TS  XTS,C  Kuptake,TS  XTS,M  Kflux,TS  XTS,B;
t  Tflux (4)
dXTG,M
dt  Kefflux,TG  XTG,C  Kuptake,TG  XTG,M; XTG,M
0  0;
t  Tflux (5)
dXTG,M
dt  Kefflux,TG  XTG,C  Kuptake,TG  XTG,M  Kflux,TG  XTG,B;























Fig. 1. Model scheme depicting the mass (X) of TGZ, TS, TG, and TGZ
quinone (TQ) in the medium (M), hepatocytes (C), and bile (B) of rat
SCH. Kuptake, Kefflux, and Kbile represent first-order rate constants for
uptake, basolateral efflux and biliary excretion, respectively. Kf, TS, Kf,
TG, and Kf, TQ represent first-order rate constants for formation of TS,
TG, and TQ, respectively. The dotted lines represent flux of TS and TG
from the bile into the incubation medium, with associated first-order
rate constants (Kflux, TS and Kflux, TG, respectively), that occurs during
incubation after the estimated time (Tflux).
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dXTQ,M
dt  Kf,TQ  XTGZ,M  Kother  XTQ,M; XTQ,M
0  0 (7)
dXTGZ,C
dt  Kuptake,TGZ  XTGZ,M  	Kf,TS  Kf,TG
  XTGZ,C;
XTGZ,C0  0 (8)
dXTS,C
dt  Kf,TS  XTGZ,C  Kuptake,TS  XTS,M  	Kefflux,TS  Kbile,TS

 XTS,C; XTS,C0  0 (9)
dXTG,C
dt  Kf,TG  XTGZ,C  Kuptake,TG  XTG,M  	Kefflux,TG  Kbile,TG

 XTG,C; XTG,C0  0 (10)
dXTS,B
dt  Kbile,TS  XTS,C; XTS,B
0  0; t  Tflux (11)
dXTS,B
dt  Kbile,TS  XTS,C  Kflux,TS  XTS,B; t  Tflux (12)
dXTG,B
dt  Kbile,TG  XTG,C; XTG,B
0  0; t  Tflux (13)
dXTG,B
dt  Kbile,TG  XTG,C  Kflux,TG  XTG,B; t  Tflux (14)
Differential equations describing the accumulation of TGZ and
derived metabolites in medium, hepatocytes and bile were fit simul-
taneously by nonlinear least-squares regression (WinNonlin Pro ver-
sion 5.0.1; Pharsight, Mountain View, CA) using a weighting scheme
of 1/(Y predicted).
Monte Carlo Simulations. Parameter estimates with associated
variance (recovered by nonlinear least-squares regression of the flux
data shown above) and uncontrolled error (experimental or analyti-
cal error; 15%) served as input for Monte Carlo simulations. To
explore hepatic TS disposition in response to impaired transport in a
hypothetical “population” of hepatocytes, simulations were per-
formed by modulating the rate constant for TS biliary excretion by
five different scenarios [experimentally determined parameter esti-
mates, 2-fold increase, 10-fold increase; 2-fold decrease, and 10-fold
decrease].
To estimate the number of observations (sample size) necessary to
detect a statistically significant difference in TS accumulation in
cells or medium due to changes in the TS biliary excretion rate
constant (Kbile, TS), data from Monte Carlo simulations at designated
time points (10, 20, 30, 60, 90, and 120 min) were analyzed using
one-way analysis of variance. Based on the effect size (the square
root of the ratio of the between-group to within-group variance)
calculated by Cohen’s f2 (Cohen, 1988), a sample size for each time
point was calculated to achieve a power of 0.80 (  0.05) by using R
packages (R Development Core Team, 2008). The relative power to
detect a statistically significant difference in medium versus cell at
each time point was calculated as a ratio of the number of observa-
tions (sample size) necessary to detect a statistically significant
difference in accumulation in medium to the number of observations
necessary for accumulation in cells.
Results
Hepatobiliary Disposition of TGZ and Derived Me-
tabolites in Human SCH. The disposition of TGZ and de-
rived metabolites in the medium and hepatocytes at 30, 60,
and 120 min is shown in Table 2; cumulative recovery of TGZ
and derived metabolites (medium  cells  bile) was 109 to
117%. At 120 min, TGZ in the medium accounted for 64.2% of
the dose. TS was the predominant metabolite of TGZ in the
medium (30.2% dose; 4543 pmol) as well as in hepatocytes
(5.64% dose; 846 pmol) during the 120-min incubation; TG
(447 pmol) and TQ (362 pmol) were recovered predominantly
in the medium (2.98 and 2.41% dose, respectively) with neg-
ligible cellular accumulation (less than 0.1% dose). Accumu-
lation of TGZ and TQ in bile was negligible. The BEI values
of TS (15–17%) and TG (41–46%) were comparable at 30, 60,
and 120 min in human SCH (Table 2).
Hepatobiliary Disposition of TGZ and Metabolites in
Rat SCH. Initial experiments confirmed that TGZ and two
preformed metabolites of TGZ, TS and TG, were taken up
into rat SCH (Fig. 2). After a 10-min incubation, average
accumulation (cells  bile) of TGZ was only slightly greater
than cellular accumulation (1600 versus 1560 pmol/mg pro-
tein), leading to a negligible BEI for TGZ of 2.3%. Average
accumulation (cells  bile) was slightly greater than cellular
accumulation for TS (2280 versus 1940 pmol/mg protein) and
TG (908 versus 605 pmol/mg protein), leading to more exten-
sive BEI values of 15 and 34% for TS and TG, respectively.
The disposition of TGZ and its derived metabolites in me-
dium, hepatocytes, and bile are plotted in Figs. 3, 4, and 5,
respectively. Cumulative recovery of TGZ and derived me-
tabolites from medium, hepatocytes, and bile was compara-
ble throughout the 120-min incubation period (90–104%)
(Table 3). At 120 min, 35.3% of the dose remained in the
medium as TGZ (Table 3). Among metabolites present in the
medium, TS was predominant (37.8% dose), followed by TG
(6.89% dose) and TQ (0.65% dose) at 120 min (Fig. 3; Table 2).
Figure 4 depicts the hepatocyte accumulation of TGZ and
derived metabolites over the 120-min incubation period. TS
formation was rapid and extensive; cellular accumulation of
TS exceeded TGZ even at 10 min (5.46 versus 1.50% of the
dose, respectively; Table 3). The cellular accumulation of TG
was 1% of the dose over the 120-min incubation. TQ accu-
mulation in the hepatocytes was negligible. The average BEI
of TS and TG was 13% and 41% over the 120-min incubation
TABLE 2
Disposition of TGZ and derived metabolites in human SCH
TGZ, TS, TG, and TQ (expressed as percentage of dose) in medium, hepatocytes, and bile at 30, 60, and 120 min after incubation in medium initially containing 10M TGZ.
BEI of TS and TG was calculated as described under Materials and Methods. Data represent mean of a single determination in n  2 livers.
Time
TGZ TS TQ TG
Recovery
Medium Cells Bile Medium Cells Bile BEI Medium Cells Bile Medium Cells Bile BEI
% dose % % dose % %
30 min 93.9 3.50 N.D. 3.69 6.27 1.29 17 2.28 0.07 N.D. 0.63 0.06 0.05 46 112
60 min 88.8 2.80 N.D. 13.3 6.61 1.22 17 2.23 0.07 N.D. 1.56 0.06 0.04 41 117
120 min 64.2 2.04 N.D. 30.2 5.64 0.99 15 2.41 0.07 N.D. 2.98 0.05 0.04 43 109
N.D., not detectable.
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time; accumulation of TGZ and TQ in bile was negligible (Fig.
5; Table 3).
Pharmacokinetic Modeling of the Hepatobiliary Dis-
position of TGZ and Its Derived Metabolites in Rat
SCH. Because data were collected at more time points in rat
SCH, a compartmental pharmacokinetic model was devel-
oped based on this data set. The model scheme depicted in
Fig. 1 best described the disposition of TGZ, TS, TG, and
TQ in rat SCH during the 120-min incubation. Represen-
tative descriptions of the best fit of the pharmacokinetic
model to the TGZ/derived metabolite versus time data are
shown as dashed lines in Figs. 3 to 5. Pharmacokinetic
parameter estimates obtained by resolving the differential
equations describing hepatocellular disposition of TGZ,
TS, TG, and TQ versus time data are included in Table 4.
The first-order rate constant for TS formation (0.383
min1) was 6-fold greater than that for TG formation
(0.061 min1). The pharmacokinetic model incorporated a
formation process for TQ from TGZ in the incubation me-
dium, instead of cellular TQ formation, because accumu-

























BEI (%)  2.3    15 ±
TG
 4              34 ± 2 
Fig. 2. Accumulation of TGZ, TS, and TG in rat SCH. Rat SCH were
treated for 10 min with 5 M TGZ, TS, or TG and accumulation (pico-
moles per milligram of protein) was measured in cells  bile (solid bars)
and in cells (open bars). Values represent the mean of triplicate determi-
nations from n  1 experiment (TGZ) or mean  S.E.M. of triplicate
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Fig. 3. Mass versus time profiles of TGZ (F), TS (E), TG (), and TQ (‚)
in the medium initially containing 10 M TGZ in day 4 rat SCH (mean 
S.E.M.; n  3 livers in triplicate). Dashed lines represent the best fit of
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the medium represented 1% of the dose throughout the 120-
min incubation period. To explain the decreased accumulation
of TS and TG in bile after 20 min, first-order rate constants for
TS and TG flux from the bile to the incubation medium were
incorporated into the pharmacokinetic model. The first-order
rate constant for TS and TG flux from the bile to the incubation
medium was 0.255 and 0.137 min1, respectively. Consistent
with data from the uptake study with preformed TGZ metabo-
lites TS and TG (Fig. 2), the first-order rate constant for TS
uptake (Kuptake,TS, 0.004 min
1) was greater than the TG up-
take rate constant (Kuptake,TG, 0.001 min
1). The first-order
rate constant for biliary excretion of TG (0.087 min1) was
2.5-fold higher than that for TS (0.035 min1). The first-order
rate constant for basolateral efflux of TG (0.135 min1) was
7.5-fold greater than that for TS (0.018 min1).
Monte Carlo Simulations. Monte Carlo simulations
were performed to assess the impact of modulation of the
first-order rate constant for biliary excretion of TS (Kbile,TS)
on the simulated hepatobiliary disposition of TS (Fig. 6). TS
cellular exposure increased from a maximum of 1378 up to
4313 pmol when Kbile,TS was decreased 2-fold, and up to 7832
pmol when Kbile,TS was decreased 10-fold; TS medium expo-
sure changed from a maximum of 5670 pmol (control) to 7579
pmol and 7219 pmol when Kbile,TS was decreased 2- and
10-fold, respectively. Overall, measurements of TS cellular
accumulation were more responsive to changes in kinetic
parameters for biliary excretion than were measurements of
TS in the medium (Table 5).
Discussion
This study examined the hepatobiliary disposition of TGZ
and its metabolites in the SCH system. Results showing
metabolism of TGZ to TS and TG confirmed that functional
activity of phase II conjugation enzymes is preserved in rat
and human SCH. In addition, pharmacokinetic modeling and
simulation studies were used to examine the impact of im-
paired biliary excretion on hepatobiliary disposition of TS
and TG in rat SCH.
Previously, Kostrubsky et al. (2000) measured metabolite
formation in conventionally cultured human hepatocytes ex-
posed to 10 M TGZ; at 1 h, concentrations of TQ were
highest in medium (depending on donor), followed by TS and
TG. We demonstrate that in human SCH exposed to 10 M
TGZ, TS was most abundant in the medium followed by TQ
and TG at 1 h. Apparent differences in metabolite formation
observed between these studies may be attributed to differ-
ences in experimental design [e.g., culture conditions (con-
ventional versus sandwich configuration), days in culture
(day 4 versus 7–8)], and/or variability in metabolic capacity
between human donors.
Transport of TGZ and its preformed metabolites was first
confirmed in rat SCH in this study. TS was taken up into
cells more efficiently compared with TG and TGZ, although
TS is more hydrophilic than TGZ. This is consistent with the
observation that TS is a higher affinity substrate than TGZ
or TG for the uptake transporter organic anion-transporting
polypeptide 1B1 (Nozawa et al., 2004). Further experiments
in rat SCH revealed that TS was the major metabolite, and
TG the next most abundant metabolite, in the medium, cells,
and bile at all time points. TQ was only detected in lesser
amounts in the medium, but not in cells or bile. Photooxida-
tion of TGZ to TQ may explain this observation (Fu et al.,
1996); thus, subsequent pharmacokinetic modeling incorpo-
rated conversion of TGZ to TQ in medium.
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Fig. 4. Mass versus time profiles of TGZ (F), TS (E), and TG () in the
hepatocytes in day 4 rat SCH; incubation medium initially contained 10
M TGZ (mean  S.E.M.; n  3 livers in triplicate). Dashed lines
represent the best fit of the pharmacokinetic model derived from the

























60 80 100 120
Fig. 5. Mass versus time profiles of TS (E) and TG () in the bile
canaliculi of day 4 rat SCH; incubation medium initially contained 10 M
TGZ (Mean  S.E.M.; n  3 livers in triplicate). Dashed lines represent
the best fit of the pharmacokinetic model derived from the scheme de-
picted in Fig. 1 to the data.
TABLE 4
Kinetic parameters estimated from compartmental pharmacokinetic
modeling analysis
TGZ (10M) was incubated in day 4 rat SCH as described under Materials and
Methods. Parameter estimates were generated by nonlinear regression of the mean
TGZ, TS, TG, and TQ data in the medium, hepatocytes and bile based on the
equations described under Materials and Methods according to the model scheme
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transported into the bile, whereas transport of TGZ into the
bile was negligible. These findings are consistent with pub-
lished reports showing that, after intravenous administra-
tion of TGZ to rats, minimal parent TGZ is recovered in bile,
whereas TS and TG (61 and 2% dose, respectively) are ex-
creted into bile (Izumi et al., 1996; Kawai et al., 1997). The
medium and biliary excretion profiles in SCH resembled the
plasma concentrations (TS  TG) and biliary excretion (TS 
TG), respectively, after oral dosing of TGZ to rats (Izumi et
al., 1997; Kawai et al., 1997). The greater amount of TS
compared with TG in rat SCH, and the greater value of Kf,TS
(0.383 min1) compared with Kf,TG (0.061 min
1) correspond
to data showing that the sulfate formation clearance was
6-fold higher than the glucuronide formation clearance in
rats (Izumi et al., 1997).
Accumulation of TS and TG in bile remained constant or
decreased during the incubation time after 20 min in both
human and rat SCH (Tables 2 and 3). To account for this,
pharmacokinetic modeling was performed to estimate rate
constants for flux of TS and TG from the bile into the medium
(Kflux), and the time of flux (Tflux) (Fig. 1; Table 4). Physio-
logical mechanisms may explain this flux; actin filament-
mediated contractility of bile canaliculi facilitates bile flow in
vivo in rat liver (Watanabe et al., 1991), and the regular,
ordered contraction of bile canaliculi has been reported pre-
viously in vitro in isolated hepatocyte couplets/hepatocyte
groups (Oshio and Phillips, 1981; Phillips et al., 1982).
Accumulation of TS and TG in the medium in rat SCH (38
and 7% of the dose, respectively) was comparable with values
obtained in human SCH (30 and 3% of the dose, respectively).
Transport proteins responsible for the basolateral excretion
of TS and TG remain to be identified. Mrp3 plays a predom-
inant role in the basolateral excretion of glucuronide conju-
gates, whereas both Mrp3 and Mrp4 are involved in the
basolateral excretion of sulfate conjugates along with addi-
tional as-yet-to-be-identified mechanism(s) (Zamek-Gliszc-
zynski et al., 2006). Pharmacokinetic modeling revealed an
7.5-fold higher first-order rate constant for basolateral ef-
flux of TG than for TS in rat SCH. This observation may
reflect more efficient basolateral efflux of TG, presumably by
Mrp3. Estimates of the rate constants for hepatocyte uptake
of TS and TG were very small relative to all other flux
estimates (Table 4). In fact, the rate constant for hepatic
uptake of TG was not recoverable with any degree of preci-
sion based on pharmacokinetic modeling of the SCH data for
TG when derived from TGZ.
Monte Carlo simulations revealed that TS cellular accu-
mulation is more responsive to changes in the rate constant
for biliary excretion of TS (Kbile,TS) than medium accumula-
tion. For example, the number of observations necessary to
observe a statistically significant difference in TS medium
exposure was always higher (4–147), compared with the
number of observations to observe a statistically significant
difference in TS hepatocyte exposure (3–14), when Kbile,TS
was modulated (Table 5). SCH data coupled with modeling
and simulation are capable of estimating the impact of al-
tered transport function on hepatic (reflected in hepatocyte
accumulation) and systemic (reflected in medium accumula-
Fig. 6. Monte Carlo simulations were performed to examine the impact of modulation of TS biliary excretion on the disposition of TS in hepatocytes
(A) and medium (B). The rate constant for biliary excretion of TS (Kbile,TS) was modulated by five different scenarios [experimentally determined
parameter estimates (black), 2-fold increase (red), 10-fold increase (green), 2-fold decrease (yellow), and 10-fold decrease (blue)].
TABLE 5
Evaluation of the sensitivity of cell and medium accumulation to detect
changes in biliary excretion of TS using data from Monte Carlo
simulations
Monte Carlo simulations were performed by modulating the rate constant for biliary
excretion of TS by three different scenarios (experimentally determined parameter
estimates; 2-fold increase; 2-fold decrease). The relative power to detect a statisti-
cally significant difference in medium vs. cell was calculated as the ratio of the
number of observations (N  sample size) necessary to detect a statistically signif-
icant difference in TS accumulation in medium to the number of observations
necessary for accumulation in hepatocytes.
Time
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tion) exposure. Peak plasma concentrations or AUCplasma
have been used to examine the effect of modulation of cana-
licular transport proteins on drug disposition, but results of
this simulation suggest that those parameters may not al-
ways reflect changes in hepatic exposure due to altered bili-
ary excretion. For example, physiologically based pharmaco-
kinetic modeling of pravastatin distribution also suggested
that plasma concentrations are not sensitive enough to detect
changes in canalicular efflux; altered canalicular efflux of
pravastatin changed liver concentrations markedly but had
minimal effect on plasma concentrations (Watanabe et al.,
2009).
The failure of preclinical testing to predict the hepatotox-
icity of TGZ emphasizes the importance of understanding the
hepatobiliary disposition and toxic potential of drugs and
metabolites in humans and in experimental animals. One
benefit of using SCH is that accumulation of parent drug and
metabolites can be measured in medium, cell, and bile com-
partments. Based on these data, the impact of altered trans-
port function on medium, cell, and bile exposure to drug and
metabolites can be assessed through pharmacokinetic mod-
eling and simulation. Efflux into medium may be analogous
to efflux from the hepatocytes into plasma in vivo, whereas
efflux into the bile may be scaled to biliary excretion in vivo.
Because data in humans regarding hepatocellular concentra-
tions of TGZ and metabolites are lacking, as are data about
efflux of TGZ or metabolites into bile, the SCH model may be
a useful in vitro tool to estimate human in vivo hepatobiliary
drug/metabolite disposition and the impact of impaired bili-
ary excretion. For example, the breast cancer resistance pro-
tein, which is expressed on the canalicular membrane of
hepatocytes, probably plays a role in the biliary excretion of
TS in humans (Enokizono et al., 2007). Based on pharmaco-
kinetic simulations, TS accumulation in hepatocytes may
increase in subjects with functional impairment of breast
cancer resistance protein. Because TGZ and TS are potent
inhibitors of Bsep/BSEP (Funk et al., 2001; Yabuuchi et al.,
2008), hepatocyte accumulation of TS could result in in-
creased susceptibility of some patients to TGZ-associated
liver injury. Based on the accumulated mass of TGZ and TS
in SCH, and the volume of rat hepatocytes (6.2  106
l/hepatocyte) (Uhal and Roehrig, 1982), intracellular con-
centrations of TGZ and TS were estimated to be 7.22 to 47.7
M and 132 to 222 M, respectively, whereas TGZ and TS
concentrations in medium were 3.53 to 9.43 and 0.05 to 3.78
M, respectively. These TGZ and TS intracellular concentra-
tions were much higher than the previously reported IC50
value of TGZ (3.9 M) and TS (0.4–0.6 M) for Bsep-medi-
ated taurocholate transport in isolated canalicular rat liver
plasma membranes (Funk et al., 2001). Cellular concentra-
tions of TS could reach 1200 M if TS biliary excretion was
impaired 10-fold based on simulations conducted in this
study. In contrast, medium concentrations of TS could in-
crease up to 4.8 M when TS biliary excretion was decreased
10-fold. Based on data generated in human SCH, and assum-
ing the same cellular volume for rat and human hepatocytes,
intracellular concentrations of TGZ and TS were estimated to
be 49.4 to 84.7 M and 136 to 160 M, respectively, through-
out the incubation period; medium concentrations were 6.42
to 9.39 M for TGZ and 0.37 to 3.03 M for TS. These
findings support the hypothesis that the potent inhibition of
BSEP by TGZ (IC50  20 M) (Yabuuchi et al., 2008) and/or
TS in the hepatocyte may contribute to TGZ-mediated liver
injury. It is important to note that medium concentrations
(analogous to systemic concentrations in vivo) considerably
underestimated cellular concentrations.
In conclusion, phase II metabolites of TGZ were detected in
both rat and human SCH, indicating the preservation of
sulfotransferase and UDP-glucuronosyltransferase function
in the SCH system. Similar TGZ metabolism and hepatobili-
ary disposition between rats and humans in vivo also was
observed in rat and human SCH, respectively, suggesting
that the SCH model is a useful in vitro tool to describe in vivo
hepatobiliary disposition of drugs and derived metabolites in
rats and humans. Pharmacokinetic modeling and simulation,
coupled with data obtained from the SCH model, may be used
as an in vitro approach to determine likely alterations in
drug/metabolite disposition, including hepatic and biliary ex-
posure in humans.
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